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Treatment of murine lupus nephritis with cyclophosphamide or total
lymphoid irradiation. Untreated 9 to 11 month-old, female NZB/W F1
mice all died within six weeks (wks) after the occurrence of nephrotic
range proteinuria ( 3 g/liter). Significant prolonged survival could be
obtained in similar groups of animals either by weekly i.v. pulses of
cyclophosphamide (CY, 25 mg/kg, 40% survival 20 wks after start of
treatment) or by administering total lymphoid irradiation (TLI, 17 daily
fractions of 2 Gy, 70% survival at 20 wks). All surviving animals in both
groups showed remission of the nephrotic range proteinuria. In all
treated mice, light microscopy examination of the kidneys revealed a
decrease of inflammation and a stabilization of proliferation and scle-
rosis, yet immunofluorescence for 1gM, IgG and C3 was not signifi-
cantly altered. The better survival of the TLI- as compared to the
CY-treated mice (P < 0.001) was due to a lower incidence of lympho-
mas or viral infections. IgG anti-DNA auto-antibodies were signifi-
cantly lowered by CY but not by TLI treatment. It is concluded that CY
pulse therapy and TLI are both efficient treatment modalities for high
grade lupus like NZB/W disease. In this model TLI is safer than CY
when used in a dose regimen of 25 mg/kglwk and interferes with the
course of the disease without lowering the IgG anti-DNA antibodies.
(NZB/NZW)F1 mice spontaneously develop an autoimmune
disease which usually manifests itself at the age of six months,
with persistent proteinuria and circulating antibodies to nucleic
acids. The primary cause of death is renal failure due to glomer-
ulonephritis [1]. The pathogenesis of the lupus syndrome in
these mice is not exactly known. A primary B cell defect with
hypersecretion of immunoglobulines and production of auto-
antibodies, defective suppressor cell activity, resistance to-
wards the induction of tolerance, genetic and viral factors, all
seem to play a role [2].
Because this animal model closely resembles human systemic
lupus erythematosis (SLE) it is generally used to better under-
stand the pathogenesis of this disease and also as a preclinical
model to investigate new treatment modalities. Recently two
new promising therapeutical approaches have been proposed to
treat human lupus nephritis. The first consists of a combination
of low dose prednisone and high i.v. pulses of cyclophospha-
mide [31. This treatment results in a better patient survival rate
as well as in a lower probability to develop renal failure when
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compared with other treatment schedules including high or low
doses of prednisone in combination or not with oral low dose
cyclophosphamide or azathioprine. Preliminary results also
indicated that the intravenous pulses of cyclophosphamide are
associated with fewer side effects than continuous oral cyclo-
phosphamide [3].
An alternative treatment proposed by investigators of Stan-
ford University is fractionated total lymphoid irradiation (TLI)
[4]. These experienints showed that TLI resulted in a long term
suppression of several cellular immune functions as well as in a
predominance of suppressor cells allowing the induction of
immunological tolerance for various antigens, including a!-
logeneic transplants. TLI has been extensively investigated as
an immunosuppressant in various experimental models by our
[5—7] and other groups [8]. For the last few years TLI has also
been used to treat patients with intractable rheumatoid arthritis
[9]. We [10] and others [11—14] showed that TLI could be
successfully administered to patients with renal insufficiency as
immunosuppression before renal transplantation. In a recent
feasibility study including a small group of patients with therapy
resistant lupus nephritis, TLI was shown to be a safe and
efficient treatment [4].
Total lymphoid irradiation and pulse therapy with cyclophos-
phamide have already been successfully used in NZBIW mice
[15, 16], but were not compared within the same experiment
and were only investigated in younger mice (respectively 6 and
5 months old) with incipient renal disease. Because we were
mainly interested in the application of both therapies for severe
lupus nephritis, only 9- to 11-month-old female mice showing
high grade proteinuria ( 3 glliter) were used in the present
study. Survival, remission of proteinuna and anti-DNA IgG
antibodies were scored at regular intervals. Because of the
prognostic value of an histological activity and chronicity index
in the clinic [17J, similar histological scores were performed on
all mice before the start of therapy and repeated at the time of
death or at the end of the study.
Methods
Animals
Inbred female (NZB/NZW)F, mice were obtained from the
Breeding and Research Center, Ry, Bomholtgard, Denmark.
Before, during and after the different treatment schedules the
animals were kept in conventional housing. At the start of the
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experiment all mice were 9 to 11 months old, and all had high
grade proteinuria as determined by the presence of proteinuria
of 3 g/liter on at least three occasions before starting the
experiment. All groups were age matched, randomly allocated,
treated simultaneously, and kept under the same conditions in
order to exclude variance in external factors (such as, infec-
tions, food) known to be able to influence the evolution of
lupus-like disease in (NZB/NZW) mice [21.
Irradiation
The irradiation technique has been described in detail else-
where [5]. Briefly, six mice were anesthetized and irradiated
simultaneously as described by Slavin et at [18]. A semiclosed
circuit inhalation anesthesia system developed in our center
[19] and enflurane was used to anesthetize the animals. Irradi-
ation was carried out using gamma rays from a 60-cobalt source
at a focus-skin distance of 60 cm (dose-rate 0.3 Gy/min). The
mice were placed in a prone position. The brain, lungs, the hind
legs and only a small part of the abdomen and pelvis were
shielded with 7 cm thick MCP (mining and chemical product
with melting point of 70°C) blocks. Seventeen fractions of 2 Gy
each were delivered each day, five days a week, up to a total
dose of 34 Gy.
Cyclophosphamide therapy
Cyclophosphamide (Cilag, Switzerland) was administered
intraperitoneally as 0.25 ml of solution in sterile 0.9% saline at
a dose of 25 mg/kg. Injections were given weekly for the whole
duration of the experiment.
Protein uria scoring
Scoring of proteinuria was estimated with Albustix (Ames,
Miles, Belgium) on fresh urine samples. This colorimetric assay
scores protein concentrations as follows: 1 = 30 mg%, 2 =
100 mg%, 3 = 300 mg%, 4 = 1000 mg%.
Histological examination
Renal biopsy. Two weeks before starting the treatment a
renal biopsy was performed in all mice. Mice were anesthe-
tized, a laparotomy was performed and a 1 mm thin slice of a
kidney pole was cut. Local hemostasis was done, and after
stopping the bleeding the abdomen was closed. This procedure
was very benign resulting in mortality in less than 3% of the
animals. At the end of the experiment or in sick mice, a
nephrectomy was done for histological examination.
Light microscopy. Tissues were fixed in 10% buffered forma-
lin, embedded in paraffin and cut at 5 jtm. Sections were stained
with hematoxylin eosin and with the periodic acid-Schiff stain
(PAS).
Immunofluorescence
Kidney tissue was sliced, quick-frozen in isopentane in a
liquid nitrogen bath, and 5 /LM thick cryocut sections were
made. The slices were incubated during 10 minutes with normal
goat or rabbit serum at 1:20 dilution. Subsequently. fluorescein-
ated goat anti-mouse antisera (Nordic, Tilburg, The Nether-
lands) to murine IgG (1:20) and C3 (1:20) and rabbit anti-mouse
anti-IgM antiserum (1:20, Nordic) was used for staining. Sec-
tions were studied for focal or diffuse staining of the glomeruli
and scored 1+ or 2 + (discrete or moderate mesangial deposi-
tion), 3 + or 4+ (discrete or moderate mesangial and subendo-
thelial deposition), 5+ or 6+ (discrete or moderate lobular
pattern with still mesangial deposits), 7+ or 8+ (moderate or
severe pure lobular pattern).
Renal histology index
Severity of renal damage was estimated by the pathologist on
blinded sections using an inflammation scale from 0 (no inflam-
mation) to 4 (severe inflammation in all glomeruli and in the
interstitium) and a mesangial proliferation-mesangial sclerosis
score. Since the increase in mesangial cells is invariably accom-
panied by an increase in mesangial matrix (that is, mesangial
sclerosis) the scoring of proliferation and sclerosis is interde-
pendent. Interstitial fibrosis, destruction of glomeruli (obsoles-
cence) is not given separately, since it did not occur in signifi-
cant quantities in any of the surviving animals. Some of the
dead animals, however, had severe glomerular obsolescence,
and are therefore considered to have died from uremia. Other
dead mice on the contrary had focal interstitial infiltrates, in
relation with the lymphoma also found in the lymph nodes. The
mesangial proliferation-mesangial sclerosis was scored ranging
from 0 (no alterations) to 1 (slight mesangial proliferation), 2
(moderate mesangial proliferation), 3 (severe mesangial prolif-
eration and early mesangial sclerosis) and 4 (severe mesangial
sclerosis and splitting of the basal membrane).
Measurement of serum antibodies to DNA
Anti-DNA IgG-antibody concentrations were assessed by a
solid phase enzyme-linked immunosorbent assay (ELISA) de-
rived from the method of Fish and Ziff [201 and described in
detail by Wofsey and Seaman [21]. Serum from adult DBA mice
and from 12-month-old untreated (NZB/W)F1 female mice
continuously showing 4+ proteinuria served as negative and
positive controls, respectively. Results were expressed as units
depending on the relative extinction of the test sera in compar-
ison with the positive control batch serum which was arbitrarily
scored as 100 units.
Results
Survival
Nine- to 11-month-old untreated control mice all died within
two months after the appearance of high grade proteinuria (3
glliter, Fig. 1). Treatment of a similar group of mice with weekly
injections of 25 mg/kg of cyclophosphamide did result in a
significantly prolonged lifespan (40% survival at 20 weeks after
the start of the experiment; P = 0.0001, logrank and Wilcoxon
rank tests). After 34 Gy of TLI the best survival rate was
observed (70% at 20 weeks after the beginning of therapy). The
survival of the TLI treated animals was significantly better than
the CY group (P = 0.017 logrank test, P = 0.015 Wilcoxon rank
test).
Mortality
Autopsy was systematically performed on animals which
were sacrificed because of severe clinical illness, or in animals
which were found dead in their cage and in which autolysis had
not progressed too far for an adequate histological diagnosis to
be made. Of the eight TLI treated mice which died, mortality
was due in three cases to the anesthesia procedure used during
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Fig. 1. Survival of 9—11 mos old (NZBIW)F1 female mice with high
grade prozeinuria after treatment with TLI (N = 27), weekly IV pulses
of cyclophosphamide (CY, N = 25), or without treatment (controls, N
= 10).
Table 1. Effect of TLI or pulse CY on IgG anti-DNA antibody levels




Pre-treatment 98.2 59.7 92.7 55.6
pb NS = 0.0039
At week 20 post- 59.7 42.1 27.9 14.8
treatment
a The level of 10 surviving mice in each group was compared with
their own pre-treatment level
b Wilcoxon signed rank test for paired data
radiotherapy; no other cause of death could be found. Of the
five remaining deaths, adequate histological data were available
in three; two of these animals had complete obsolescence of all
glomeruli, and in one a thymoma was found. Histological data
were available in 10 of the 15 Cy treated animals which died. In
two of them mortality was related to a disseminated viral
infection, in five to a disseminated lymfoma and in three to
generalized glomerular obsolescence.
Evolution of proteinuria
In none of the control animals was a decrease of proteinuria
(2+) observed during their limited lifespan. TLI and CY
treatment both resulted in a decrease of proteinuria ( 1+) in an
increasing number of the surviving animals (respectively 94%
and 78% at 10 weeks and 100% in both groups at 20 weeks after
the start of treatment).
Evolution of anti-DNA IgG antibodies
At the start of treatment all animals in both treatment groups
had similar high levels of anti-DNA IgG auto-antibodies (re-
spectively 98.2 units and 92.7 units in the TLI and CY groups,
Table 1). After 20 weeks anti-DNA antibodies had decreased in
both groups but this decrease was only significant in the CY
group (P = 0.0039 Wilcoxon signed rank test for paired data),
and not in the TLI group. Some of the TLI mice had even a
significant rise of their anti-DNA antibody levels, whereas this
was never observed in any of the surviving CY treated mice.
Table 2. Effect of TLI or pulse CY on the light microscopy histology
score in female NZB/W mice with high grade lupus-like diseasea
TLI CY
Inflammation score pretreatmentb 3.5 (1.5—3.5) 2.5 (2—4)
P <0.05 <0.05
Inflammation score post-treatment 0.5 (0—1) 1.0 (0—3)
Mesangial proliferation and mesangial 1.0 (0—2) 2.5 (1—3)
Sclerosis score pre-treatment
P NS NS
Mesangial proliferation and mesangial 1.0 (0—1) 1.0 (0.5—3)
Sclerosis score post-treatment
a Only data of the subgroup of surviving mice of which pre- and post-
treatment histology is available are given.
b Median (range)
Wilcoxon signed rank test and Mann Whitney test
Evolution of the renal histology and immunofluorescence
score
Before starting the treatment renal biopsy was done in all
mice. Animals allocated to TLI or CY were not significantly
different for inflammation score (resp. median 3.7 (range I to 4)
versus median 3.5 (range I to 4)) or mesangial proliferation or
mesangial sclerosis score [respectively, median 1.2 (range 0 to
4) versus median 1.1 (range 0 to 3)]. Table 2 shows the evolution
of the light microscopy histology score of the surviving mice as
compared with their own pre-treatment value. Both treatments
did result in a significant decrease of the inflammation score (P
<0.05, Wilcoxon signed rank test and Mann Whitney test) at
the end of the experiment and also in a stabilization of the
mesangial proliferation and sclerosis index. The immunofluo-
rescence scores for IgG, 1gM and C3 were not significantly
altered by either treatment (data not shown).
Discussion
Recent preliminary reports showed promising results with
both total lymphoid irradiation (TLI) [4] and i.v. pulses of
cyclophosphamide (pulse CY) [3] in patients with lupus glomer-
ulonephritis. The major aim of the present study was to
compare the relative efficacy of both treatments within one
study in an animal model of lupus. At the same time the effect
of the two treatment modalities on the renal histology score and
anti-DNA antibody levels was investigated.
The first conclusion which can be drawn is that TLI and pulse
CY are both effective in treating high grade, (NZB/W)F1 lupus-
like glomerulonephritis This extends to previous reports dealing
with TLI [15] or pulse CY [16] in younger (5 to 6 months old)
(NZB/W) mice with incipient disease, since the present study
demonstrates that TLI and pulse CY are also active in older
animals (9 to 11 months) with advanced disease and nephrotic
range proteinuria. Indeed, high grade proteinuria disappeared in
all treated mice. As far as survival was concerned, terminal
renal failure as documented by total obsolescence of all glomer-
uli was only observed in a minority of the animals in both
groups. TLI was however safer than pulse CY in a dose regimen
(25 mgikglwk) as used in the present study. The excess mortal-
ity of the CY treatment was mainly due to a high incidence of
lymphomas and viral infections. Extrapolations from this ob-
servation to the clinical situation must be made with care.
Firstly, NZB/W mice have a high natural tendency to develop
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lymphomas [22]. Secondly, the present CY regimen is maybe
not the most safe one. Although it has been shown that the
number of lymphomas increased with the size of daily dose of
cyclophosphamide in NZB/W mice [23], there seems to be no
correlation between the incidence of lymphomas and the cumu-
lative dose of drug or number of weeks in the treatment period
[23]. It can therefore be expected that increasing the interval of
dosing of CY from, for example, one week to one month may
significantly reduce the risk of lymphoma. Hence it is likely that
another pulse schedule (90 mg/kg/month) which has been shown
to be also highly effective [16] is likely to be associated with less
side effects. The clinical experience with pulse CY administered
with monthly intervals seems to confirm this [3]. Moreover,
although it is known that cyclophosphamide can result in an
increased incidence of malignancy in man [24], this risk is
certainly lower than in the present experiment. Thirdly, al-
though TLI was very safe with regards to secondary cancers
when used without concomitant cytotoxic drugs in patients with
Hodgkin's disease [25], the follow-up in other groups of TLI
treated pateints is still too short to exclude all risks of malig-
nancy. Finally, the high incidence of viral infections in the pulse
CY group may be related to leucopenia, which was not moni-
tored in the present study before administering a new CY pulse,
and which of course would be anticipated in clinical circum-
stances. The questions about the respective risks of TLI or
pulse CY for the treatment of human lupus nephritis will only be
solved by a controlled clinical trial, which seems highly indi-
cated now.
Another point which must be raised is that human lupus is an
heterogeneous disease and that the (NZB/W)F1 model is only
relevant to a subgroup of patients. Finding a high efficacy with
TLI in the present model certainly does not guarantee a high
success rate in patients. However, the fact that TLI was also
shown to be effective in MRL mice [26], another murine lupus
model with different pathogenesis and which is resistant to
pulse CY [16], may suggest that TLI may be successful in
various subgroups of lupus patients.
Light miscroscopy examination of the kidneys revealed that
inflammation had almost disappeared and that proliferation and
sclerosis had not significantly progressed in mice treated with
both regimens. It has been shown that the renal histology index
is one of the most reliable prognostic factors for lupus nephritis
[17]. The similarly strong influence of TLI and pulse CY on the
evolution of the histology score in the present experiment thus
further illustrates their potent action. It is also of interest to
mention that in the TLI treated animals no signs of radiation
induced damage could be demonstrated, despite the fact that
the kidneys had been exposed to 17 fractions of 2 Gy because of
the large abdominal TLI fields used in the murine model.
A fascinating observation in the present study was that,
whereas pulse CY leads to a significant decrease of the anti-
DNA IgG auto-antibodies, remission was obtained with TLI
without a significant fall of these antibodies. In several TLI
treated mice, anti-DNA IgG had even risen despite a disappear-
ance of proteinuria. A similar discrepancy between an im-
proved clinical and immunopathological evolution, and un-
changed auto-antibodies was recently also observed in MRL
mice treated with cyclosporin A [27]. Hence, it seems that TLI
does influence another (possibly cellular) pathway in the patho-
genesis of (NZB/NZW) glomerulonephritis. TLI treated ani-
mats with persistent high levels of anti-DNA antibodies thus
furnish an interesting model to explore the mechanisms which
determine the full expression of lupus kidney disease beside
anti-DNA antibodies. We are presently investigating this fur-
ther by transferring cells from and to TLI treated (NZB/
NZW)F1 mice.
In conclusion, the present study shows that TLI and pulse
CY are both efficient therapies for high grade, (NZB/NZW)F1
lupus-like glomerulonephritis and able to induce clinical as well
as histological remission. In this model IL! is safer mainly
because of a lower lymphoma or viral infection related mortal-
ity. In contrast to pulse CY, TLI does cure without significantly
lowering the anti-DNA IgG antibodies. A controlled clinical
trial including TLI is presently much needed for lupus patients
since firstly, IL! was already shown to be an effective im-
munosuppressant in other clinical situations [9—14], secondly,
its. efficacy was already demonstrated in a preliminary uncon-
trolled study dealing with intractable lupus patients [4], thirdly,
in the present study TLI was the most active and safe modality
for high grade lupus-like glomerulonephritis.
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